about
BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccinationTremelimumab: research and clinical developmentLymphoma Immunotherapy: Current StatusThe Yin and Yang of Toll-like receptors in cancerRadiation as immunomodulator: implications for dendritic cell-based immunotherapyRoutes of delivery for CpG and anti-CD137 for the treatment of orthotopic kidney tumors in miceEarly experience with novel immunomodulators for cancer treatmentDiet-induced obesity alters dendritic cell function in the presence and absence of tumor growthGene expression meta-analysis identifies metastatic pathways and transcription factors in breast cancerA novel cancer vaccine strategy based on HLA-A*0201 matched allogeneic plasmacytoid dendritic cells.Autophagy facilitates TLR4- and TLR3-triggered migration and invasion of lung cancer cells through the promotion of TRAF6 ubiquitination.Tumor vaccine composed of C-class CpG oligodeoxynucleotides and irradiated tumor cells induces long-term antitumor immunity.Short- and long-term changes in gene expression mediated by the activation of TLR9Innate immunity and inflammation in systemic sclerosisAnti-tumor immune response correlates with neurological symptoms in a dog with spontaneous astrocytoma treated by gene and vaccine therapy.Treatment with LL-37 peptide enhances antitumor effects induced by CpG oligodeoxynucleotides against ovarian cancerComplement activation by CpG in a human whole blood loop system: mechanisms and immunomodulatory effects.Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression.Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells.Toll-like receptor agonists: are they good adjuvants?TLR9 is critical for glioma stem cell maintenance and targeting.Systemic treatment with CpG-B after sublethal rickettsial infection induces mouse death through indoleamine 2,3-dioxygenase (IDO).A strategy of tumor treatment in mice with doxorubicin-cyclophosphamide combination based on dendritic cell activation by human double-stranded DNA preparation.Superior efficacy of tumor cell vaccines grown in physiologic oxygenPitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909.Early development of the Toll-like receptor 9 agonist, PF-3512676, for the treatment of patients with advanced cancers.Targeting Stat3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T cells.CpG-Oligodeoxynucleotide Treatment Protects against Ionizing Radiation-Induced Intestine Injury.Tumor immunotherapy using adenovirus vaccines in combination with intratumoral doses of CpG ODNResults of multicenter double-blind placebo-controlled phase II clinical trial of Panagen preparation to evaluate its leukostimulatory activity and formation of the adaptive immune response in patients with stage II-IV breast cancerCombination of cyclophosphamide and double-stranded DNA demonstrates synergistic toxicity against established xenografts.CpG and non-CpG oligodeoxynucleotides directly costimulate mouse and human CD4+ T cells through a TLR9- and MyD88-independent mechanismDifferential toll-like receptor 3 (TLR3) expression and apoptotic response to TLR3 agonist in human neuroblastoma cells.Systemic administration of CpG oligodeoxynucleotide and levamisole as adjuvants for gene-gun-delivered antitumor DNA vaccines.Brucella spp. Lumazine Synthase Induces a TLR4-Mediated Protective Response against B16 Melanoma in Mice.Design and Structural Requirements of the Potent and Safe TLR-9 Agonistic Immunomodulator MGN1703.In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study.Eradication of metastatic renal cell carcinoma after adenovirus-encoded TNF-related apoptosis-inducing ligand (TRAIL)/CpG immunotherapyPivotal role of ADP-ribosylation factor 6 in Toll-like receptor 9-mediated immune signalingTriggering of Toll-like Receptor-2 in Mouse Myelomonocytic Leukaemia Cells WEHI-3B Leads to the Suppression of Apoptosis and Promotes Tumor Progression in Vivo.
P2860
Q24652965-CBF3CAF1-C34C-4182-B97B-CEA2F757A888Q26752822-049E194B-56E2-42F4-A995-8C948581AB25Q26782902-51910398-08DC-4EBA-8A10-4CF921698D42Q26851526-DBF51251-D7A6-407B-999A-6CCF5C94EA09Q27025756-2B45537B-C665-4F27-931D-535DA3087851Q27335400-8901ABCB-C23A-41DF-AEEC-879E6E553ED3Q28241744-11963A75-17AB-41DA-B95C-80437A1AD1D7Q28386614-E0DB7434-4A79-43DA-94CB-75C90A8C9AEAQ33396559-4042C07C-54CB-4703-B9EE-E2E123E9C516Q33573323-7A6080C9-0570-40C8-B343-2A377E50BEB6Q33577585-92A743AD-4BAA-4DBA-8436-EDEE9965A73CQ33690978-BCA70757-EE63-4E91-8B5A-90743CD4A26AQ33695664-CE08687D-5E28-4346-B3A8-CBD03F285863Q33767356-56251EE9-9F04-41C5-8F17-D444EAE6DE36Q33789543-1E03B4BA-8E12-4D68-A508-F12A2F536610Q33792003-FA7C4028-D161-4D53-9768-FBA333D09A10Q33801802-6F1D763B-C421-4EDB-9281-DF51E89D0561Q33903025-60BB9402-11AC-4BB8-9C4B-19B51C3E0E33Q33931707-66BE0326-7131-4788-9B7A-459CFEEB722FQ34067537-A6B1846F-D5FE-409D-A5E0-D64D27CC3013Q34204722-AF385B9D-9479-4A64-90E3-87C8413E1C03Q34217664-F4ED7F28-D50A-4DBF-9C12-B040FF465066Q34330865-3C4E0567-ADE3-4798-8627-711FDB9442FBQ34468716-6E70F098-DDEF-41E5-8060-BE42CB79F971Q34508125-362D3069-2757-4E64-B35D-19D2ECF75F1DQ34619324-9026FF25-70D3-407F-8103-144F214D277AQ34681856-F9EB526B-4D48-4CCD-9A4E-8080705DCB26Q34785434-9EBF8982-EC2D-46E2-89EC-5623D10B70E6Q35174485-6E471B16-2540-4C76-8F5D-A6E018DEB207Q35194151-60300475-80A0-4B3C-B57B-930EFD6021DBQ35204204-7DF87972-54D9-456A-92A3-14312310DDEFQ35204579-4F73FAFB-9605-4FA5-AA5D-2C8E2BAE27ECQ35248327-20D36A97-851C-4747-AFD6-FB2D30A4BB0FQ35417954-C6E34155-E654-4F46-A2BA-0CCD3D0C42ACQ35606746-AFC0BB3A-01AD-45F6-B806-3C0DDD909BE8Q35635250-17BDA74C-72BF-4C9B-A84F-F822DA79ADFDQ35669197-63E0B1D5-BE1D-40CE-8B45-960260B27167Q35721553-B77D5F5F-7C54-40DE-8AE8-E03FD47C3BB0Q35763211-AD20302A-80CA-4CF6-BC62-30ACECFCAF45Q35944516-F23309CC-3CE5-49E4-9FC5-FBF4B2A10C5E
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Development of TLR9 agonists for cancer therapy
@ast
Development of TLR9 agonists for cancer therapy
@en
type
label
Development of TLR9 agonists for cancer therapy
@ast
Development of TLR9 agonists for cancer therapy
@en
prefLabel
Development of TLR9 agonists for cancer therapy
@ast
Development of TLR9 agonists for cancer therapy
@en
P2860
P356
P1476
Development of TLR9 agonists for cancer therapy
@en
P2093
Arthur M Krieg
P2860
P304
P356
10.1172/JCI31414
P407
P577
2007-05-01T00:00:00Z